Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Oral Investigations
Published in: Clinical Oral Investigations 6/2015

01-07-2015 | Original Article

Nitric oxide-mediated cytotoxic effect induced by zoledronic acid treatment on human gingival fibroblasts

Authors: Marianna De Colli, Susi Zara, Viviana di Giacomo, Antonia Patruno, Guya Diletta Marconi, Marialucia Gallorini, Vincenzo Luca Zizzari, Giulia Tetè, Amelia Cataldi

Published in: Clinical Oral Investigations | Issue 6/2015

Login to get access

Abstract

Objectives

The aim of our work was to evaluate the role of nitric oxide (NO) in the in vitro response of human gingival fibroblasts (HGFs) to 1, 5, 10, and 100 μM doses of zoledronic acid (ZA), a bisphosphonate largely used in the clinical practice and for which several adverse effects are reported.

Materials and methods

Phase contrast microscopy and live/dead staining were used to evaluate HGFs morphology; cell viability, collagen type I and interleukin 6 (IL-6) secretion were evaluated by 3-[4,5-dimethyl-thiazol-2-yl-]-2,5-diphenyl tetrazolium bromide (MTT) and enzyme-linked immunosorbent assay (ELISA) assays. Reactive oxygen species (ROS) production and mitochondrial membrane potential were evaluated by flow cytometry; NO production and NOS activity by spectrophotometric analysis; endothelial NOS (eNOS) and neuronal NOS (nNOS) expression by immunofluorescence.

Results

Viable fibroblasts are evidenced in control sample while floating dead cells and cells close to detachment phase in ZA-treated sample, in agreement with decreased level of collagen type I. Control sample shows higher number of viable cells respect to ZA-treated one and ROS production increases when ZA is added. Released NO in ZA-treated sample appears higher and NO overproduction is related to increased nNOS activity. IL-6 secretion level is higher in ZA-treated sample than in control one.

Conclusions

Our results suggest ROS involvement in NO overproduction, due to nNOS recruitment, both at low and high doses. In turn, NO release seems to be able to trigger the inflammatory response only when high doses are administered, thus confirming the ZA cytotoxic effect on HGFs.

Clinical relevance

The knowledge of ZA-mediated cytotoxicity mechanisms on HGFs allows to better understand drug pharmacological activity.
Literature
1.
Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A (2005) Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 136:1669–74PubMedCrossRef
2.
Hillner BE, Ingle JN, Chlebowski RT et al. (2004) American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042–57. Erratum in: J Clin Oncol 2004; 22: 1351
3.
Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377–87PubMed
4.
Vincenzi B, Santini D, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–51PubMedCrossRef
5.
Major P (2002) The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 7:481–91PubMedCrossRef
6.
7.
Goffinet M, Thoulouzan M, Pradines A et al (2006) Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 15(6):60CrossRef
8.
Civitelli R, Napoli N, Armamento-Villareal R (2007) Use of intravenous bisphosphonates in osteoporosis. Curr Osteoporos Rep 5:8–13PubMedCrossRef
9.
Rizos EC, Milionis HJ, Elisaf MS (2006) Fever with rash following zoledronic acid administration. Clin Exp Rheumatol 24:455PubMed
10.
Bagan JV, Jimenez Y, Murillo J et al (2006) Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 42:327–9PubMedCrossRef
11.
Kyrgidis A, Triardis S, Antoniades K (2009) Effects of bisphosphonates on keratinocytes and fibroblasts having a role in the development of osteonecrosis of the jaw. Byosciences Hypotheses 2:153–159CrossRef
12.
Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41:318–20PubMedCrossRef
13.
Hoefert S, Schmitz I, Weichert F, Gaspar M, Eufinger H (2014) Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases. Clin Oral Investig
14.
Scheper M, Chaisuparat R, Cullen K, Meiller T (2010) A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair 3:6PubMedCentralPubMedCrossRef
15.
Cozin M, Pinker BM, Solemani K et al (2011) Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts. J Oral Maxillofac Surg 69:2564–78PubMedCentralPubMedCrossRef
16.
Açil Y, Möller B, Niehoff P et al (2012) The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Craniomaxillofac Surg 40:e229–35PubMedCrossRef
17.
Ohnuki H, Izumi K, Terada M et al (2012) Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes. Arch Oral Biol 57:906–17PubMedCrossRef
18.
Kang SW, Park HJ, Ban JY, Chung JH, Chun GS, Cho JO (2011) Effects of nicotine on apoptosis in human gingival fibroblasts. Arch Oral Biol 56:1091–7PubMedCrossRef
19.
Cataldi A, Zara S, Rapino M, Patruno A, di Giacomo V (2013) Human gingival fibroblasts stress response to HEMA: a role for protein kinase C α. J Biomed Mater Res A 101:378–84PubMedCrossRef
20.
21.
Park HS, Lee SH, Park D et al (2004) Sequential activation of phosphatidylinositol 3-kinase, beta Pix, Rac1, and Nox1 in growth factor-induced production of H2O2. Mol Cell Biol 24:4384–94PubMedCentralPubMedCrossRef
22.
Beckman KB, Ames BN (1998) The free radical theory of aging matures. Physiol Rev 78:547–81PubMed
23.
Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C (2012) The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 10:4–18PubMedCrossRef
24.
Chung HT, Pae HO, Choi BM, Billiar TR, Kim YM (2001) Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun 282:1075–9PubMedCrossRef
25.
26.
Titheradge MA (1998) The enzymatic measurement of nitrate and nitrite. Methods Mol Biol 100:83–91PubMed
27.
Patruno A, Pesce M, Marrone A et al (2012) Activity of matrix metallo proteinases (MMPs) and the tissue inhibitor of MMP (TIMP)-1 in electromagnetic field-exposed THP-1 cells. J Cell Physiol 227:2767–74PubMedCrossRef
28.
Defrere S, Lousse JC, Gonzalez-Ramos R et al (2008) Potential involvement of iron in the pathogenesis of peritoneal endometriosis. Mol Hum Reprod 14:377–385PubMedCrossRef
29.
Zhen J, Lu H, Wang XQ, Vaziri ND, Zhou XJ (2008) Upregulation of endothelial and inducible nitric oxide synthase expression by reactive oxygen species. Am J Hypertens 21:28–34PubMedCrossRef
30.
Murata M, Thanan R, Ma N, Kawanishi S (2012) Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J Biomed Biotechnol 2012:623019PubMedCentralPubMedCrossRef
31.
Jiang ZL, Zhu X, Diamond MP, Abu-Soud HM, Saed GM (2008) Nitric oxide synthase isoforms expression in fibroblasts isolated from human normal peritoneum and adhesion tissues. Fertil Steril 90:769–74PubMedCentralPubMedCrossRef
32.
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 87:1620–1624PubMedCentralPubMedCrossRef
33.
Maron BA, Michel T (2012) Subcellular localization of oxidants and redox modulation of endothelial nitric oxide synthase. Circ J 76:2497–512PubMedCrossRef
34.
Medina EA, Morris IR, Berton MT (2010) Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain. J Immunol 185:7562–72PubMedCrossRef
35.
Tipton DA, Seshul BA, Dabbous MKH (2011) Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. J Periodontal Res 46:39–47PubMedCrossRef
36.
Saracino S, Canuto RA, Maggiora M et al (2012) Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model. J Oral Pathol Med 41:788–92PubMedCrossRef
37.
Fraisl P (2013) Crosstalk between oxygen- and nitric oxide-dependent signaling pathways in angiogenesis. Exp Cell Res 319:1331–9PubMedCrossRef
38.
39.
Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C (2014) Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Investig 18:1015–22PubMedCrossRef
40.
Ziebart T, Pabst A, Klein MO, Kämmerer P, Gauss L, Brüllmann D, Al-Nawas B, Walter C (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis:inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15:105–11PubMedCrossRef
Metadata
Title
Nitric oxide-mediated cytotoxic effect induced by zoledronic acid treatment on human gingival fibroblasts
Authors
Marianna De Colli
Susi Zara
Viviana di Giacomo
Antonia Patruno
Guya Diletta Marconi
Marialucia Gallorini
Vincenzo Luca Zizzari
Giulia Tetè
Amelia Cataldi
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Clinical Oral Investigations / Issue 6/2015
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-014-1344-9

Other articles of this Issue 6/2015

Clinical Oral Investigations 6/2015 Go to the issue

Original Article

Increased periodontal inflammation in women with preterm premature rupture of membranes

Original Article

MTA versus Ca(OH)2 in apexification of non-vital immature permanent teeth: a randomized clinical trial comparison

Review

Effectiveness of maxillary protraction using facemask with or without maxillary expansion: a systematic review and meta-analysis

Original Article

Development and validation of the German version of the Orofacial Esthetic Scale

Original Article

Elevated insulin resistance in patients with recurrent aphthous stomatitis

Original Article

Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ)